Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses

A 45-year-old male patient with moderate-to-severe plaque psoriasis presents for follow-up. His baseline PASI score was 22, baseline IGA was 4, and baseline BSA involvement was 25%. He has no prior biologic treatment but has used topical corticosteroids and phototherapy in the past. He has been on guselkumab 100 mg every 8 weeks for 3 years and is concerned about the long-term effectiveness of his therapy given his high baseline disease severity.

Based on the VOYAGE 1 and 2 post hoc analyses, what is the most accurate statement regarding the expected long-term efficacy of guselkumab in this patient?

Patients with baseline PASI ≥20 and IGA=4 typically show significantly lower sustained response rates compared to those with milder baseline disease.
Guselkumab demonstrates sustained high rates of IGA 0/1 and PASI 90 responses through 5 years regardless of baseline disease severity, including patients with PASI ≥20 and IGA=4.
Patients with baseline BSA ≥20% generally do not maintain PASI 90 responses beyond 2 years of treatment with guselkumab.
Long-term efficacy of guselkumab is only maintained in patients with baseline PASI <20 and IGA ≤3.

A 52-year-old female with moderate-to-severe plaque psoriasis has been on guselkumab 100 mg every 8 weeks for 4 years. Her prior treatment history includes multiple nonbiologic systemic therapies and biologic agents (etanercept and ustekinumab) with suboptimal responses. She is concerned about her prognosis and the likelihood of sustained skin clearance given her prior biologic exposure.

According to the VOYAGE 1 and 2 post hoc analyses, how does prior biologic therapy exposure affect the long-term efficacy of guselkumab in patients with moderate-to-severe psoriasis?

Prior biologic use is associated with a markedly higher sustained PASI 90 response rate compared to biologic-naïve patients.
Patients with prior biologic exposure have modestly lower sustained IGA 0/1 and PASI 90 response rates compared to biologic-naïve patients, but still maintain substantial efficacy.
Guselkumab is ineffective in patients with prior biologic treatment history and should be avoided in this population.
Prior use of nonbiologic systemic therapies, but not biologics, negatively impacts guselkumab's long-term efficacy.

A 38-year-old Asian female with moderate-to-severe plaque psoriasis has been treated with guselkumab for 5 years. She is concerned about the safety of continuing this biologic long-term and asks about the risk of serious adverse events, including infections or inflammatory bowel disease.

What evidence-based information should the pharmacist provide regarding the long-term safety profile of guselkumab based on the VOYAGE studies and related pooled analyses?

Long-term treatment with guselkumab is associated with a high risk of opportunistic infections and inflammatory bowel disease, requiring frequent monitoring.
Pooled analyses including VOYAGE trials demonstrate a favorable long-term safety profile with no increased risk of Crohn's disease, ulcerative colitis, or opportunistic infections over 5 years.
Guselkumab has not been studied beyond 2 years, so long-term safety data are unavailable.
Guselkumab has not been studied beyond 2 years, so long-term safety data are unavailable.
Patients of Asian descent have a significantly higher incidence of adverse events with guselkumab compared to the global population.

Quiz Summary

Information

Results

Results

Categories

1. Question

2. Question

3. Question